Tarsus Pharmaceuticals (TARS) EBIAT (2020 - 2025)
Historic EBIAT for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to -$12.6 million.
- Tarsus Pharmaceuticals' EBIAT rose 4626.39% to -$12.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$81.2 million, marking a year-over-year increase of 3958.9%. This contributed to the annual value of -$115.6 million for FY2024, which is 1496.69% up from last year.
- Latest data reveals that Tarsus Pharmaceuticals reported EBIAT of -$12.6 million as of Q3 2025, which was up 4626.39% from -$20.3 million recorded in Q2 2025.
- Tarsus Pharmaceuticals' EBIAT's 5-year high stood at $10.4 million during Q1 2021, with a 5-year trough of -$41.9 million in Q4 2023.
- Over the past 5 years, Tarsus Pharmaceuticals' median EBIAT value was -$22.5 million (recorded in 2022), while the average stood at -$20.3 million.
- In the last 5 years, Tarsus Pharmaceuticals' EBIAT soared by 63019.93% in 2021 and then crashed by 44717.05% in 2023.
- Quarter analysis of 5 years shows Tarsus Pharmaceuticals' EBIAT stood at -$14.9 million in 2021, then grew by 8.43% to -$13.6 million in 2022, then crashed by 208.13% to -$41.9 million in 2023, then soared by 44.84% to -$23.1 million in 2024, then surged by 45.55% to -$12.6 million in 2025.
- Its EBIAT was -$12.6 million in Q3 2025, compared to -$20.3 million in Q2 2025 and -$25.1 million in Q1 2025.